Plain-English translation of NCT05393791 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new approach to treating advanced prostate cancer that no longer responds to standard hormone therapy. Instead of taking abiraterone or (the medications used) every single day until they stop working, researchers want to see if stopping and starting the medication in cycles—based on your PSA levels—might help the treatment work longer and cause fewer side effects.
All prostate cancer eventually develops resistance to this medication, meaning it stops working. Doctors believe that by pausing treatment at the right times, sensitive cancer cells will survive and compete with resistant cells, slowing down the cancer's ability to become completely resistant to the treatment.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either take the medication continuously (as is standard) or to follow an adaptive schedule where the medication pauses when your PSA drops by more than 50% and restarts when it rises back to baseline levels. You will have regular PSA blood tests and scans to monitor your cancer, and the study team will track your side effects and overall health throughout the trial.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Australia